Medication info
Oloduet Tablet 20/5 mg

Oloduet Tablet 20/5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
White or off-white round film-coated tablet
Packaging
30 tablets/box [10 tablets/Alu-Alu*3]
Approval status
Active

MFDS item code 202003973 · Approved 2020.05.28

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is used for patients who need to take two components, Olmesartan Medoxomil and Rosuvastatin together. Olmesartan Medoxomil primarily helps in treating essential hypertension. Rosuvastatin is used to improve hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise. Additionally, it has the effect of reducing the risk of cardiovascular disease and slowing the progression of atherosclerosis. This medication helps reduce the risks associated with stroke, myocardial infarction, and vascular reformation. Therefore, it is used to improve overall cardiovascular health through blood pressure control and lipid management.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used in women who are allergic to any ingredients, pregnant or nursing, or in patients with severely compromised renal function. Administration should also be avoided in patients with severely impaired renal or liver function, biliary obstruction, muscle diseases, or when used in combination with certain medications. Careful monitoring is required for patients with significantly low blood pressure or reduced blood volume due to the risk of hypotension. This medication may increase serum potassium levels, posing a risk of hyperkalemia, particularly in patients with kidney disease or heart failure, requiring regular potassium level monitoring. Muscle pain, muscle weakness, and rarely severe muscle damage (rhabdomyolysis) may occur, and if any muscle-related symptoms appear, medical assistance must be sought immediately. Liver function abnormalities may occur, so regular liver function tests are recommended before and during treatment. Due to potential side effects such as dizziness, caution is advised while driving or operating dangerous machinery. The risk of side effects may increase when used in combination with certain medications, so if any other medications are being taken, the healthcare provider must be informed. The safety and efficacy of this drug in children and adolescents under 18 years have not been established, so its use is not recommended. In elderly patients, dosage adjustments and careful monitoring are advised due to potential increased drug concentration. In case of overdose, symptoms such as hypotension and palpitations may occur, and appropriate treatment should be received if necessary. This medication should be stored out of the reach of children and should not be transferred to another container.

Side effects

Elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, decreased sensation, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute kidney failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, facial edema, low back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and the storage temperature should be maintained between 1°C to 30°C. This will ensure the medication's effectiveness is safely preserved.

Appearance and packaging

Appearance

White or off-white round film-coated tablet

Package unit

30 tablets/box [10 tablets/Alu-Alu*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.